SYF95067bf6a0b34fb898a91b3cb5e0551bRegistry ID: 2023-503698-40-00|RecruitingPhase 3
Loading search results
Secondary identifiers
interventional
N/A
11 countries
19
To determine the effect of low-dose aspirin on theincidence of preterm preeclampsiawith delivery <37 weeks’ gestation.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 28, 2023
Actual (reported)To determine if the prophylactic use of low-dose aspirin from the first-trimester of pregnancy in women with twin pregnancy can reduce the incidence of PE with delivery <37 weeks’ gestation.
To determine the effect of low-dose aspirin on the incidence of (stratified according to chorionicity): Delivery with PE at <32 weeks, <34 weeks, <37 weeks and at any gestation.
Gestational hypertension (GH)
Birth at <32 weeks, <34 weeks and <37 weeks (Spontaneous, Iatrogenic for PE, GH or FGR, Iatrogenic for other reason).
Death of one twin and / or both twins before discharge from hospital: Miscarriage of the whole pregnancy or death of one twin <24 weeks’ gestation, Stillbirth or neonatal death of one or both twins at <32 weeks, <34 weeks, <37 weeks and at any gestation.
Birthweight <3rd, <5th and <10th percentile for gestational age
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Aspirin 75mg Gastro-resistant Tablets
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
GASTRO-RESISTANT TABLET
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Aspirin 75mg Gastro-resistant Tablets
Named ingredient: Acetylsalicylic Acid
View registry recordVseobecna Fakultni Nemocnice V Praze
Prague, 128 00, Czechia
Hippokration Hospital
Thessaloniki, 546 42, Greece
Areteio Hospital
Athens, 115 28, Greece
Catalina de Paco Matallana
First Submitted
February 28, 2023
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Prevention of Preeclampsia With Aspirin in Recipients of Donated Oocytes.
Contact the study team to confirm eligibility.
General Hospital Of Thessaloniki Papageorgiou
Efkarpia, 564 29, Greece
Alexandra Hospital
Athens, 115 28, Greece
Katholieke Universiteit Te Leuven
Leuven, 3000, Belgium
Hospital Quironsalud Malaga
Malaga, 29004, Spain
Hospital Universitari Dexeus Grupo Quironsalud
Barcelona, 08028, Spain
Hospital Universitario De Cruces
Barakaldo, 48903, Spain
Hospital Universitari Vall D Hebron
Barcelona, 08035, Spain
Hospital Universitario De Canarias
La Laguna, 38320, Spain
University Clinical Hospital Virgen De La Arrixaca
Murcia, 30120, Spain
Complexo Hospitalario Universitario A Coruna
A Coruna, 15006, Spain
Hospital Universitario Clinico San Cecilio
Granada, 18016, Spain
Hospital Universitario de Torrejon
Torrejon De Ardoz, 28850, Spain
Specialized Obstetrics And Gynecology Hospital For Active Treatment Dr. Shterev EOOD
Sofia, 1330, Bulgaria
Medical center Oscar Clinic OOD
Sofiya, 1407, Bulgaria
Medical University Of Vienna
Vienna, 1090, Austria
Rigshospitalet
Copenhagen Oe, 2100, Denmark